1. Introduction
===============

Direct antiviral agent (DAA) has been the standard of care for patients with hepatitis C virus (HCV) infection. The current strategy has moved to interferon-free regimens. The mainstream treatment duration are 12 to 24 weeks depending on regimens and patient characteristics.^\[[@R1]\]^ Paritaprevir/ritonavir/ombitasvir plus dasabuvir (PROD) with or without ribavirin has shown to have a sustained virological response at post-treatment 12 weeks (SVR12) rate of \>90% in HCV genotype 1 (HCV-1) patients. In addition to the development of pangenotypic, high potency DAAs, efforts now are made trying to abbreviate treatment duration to 4 to 8 weeks without compromising efficacy. We herein report an HCV-1b patient who received only 25 days of PROD treatment. The patient early terminated treatment due to dengue fever but eventually achieved SVR12.

2. Patient information, therapeutic Intervention, follow-up, and outcome
========================================================================

The 81-year-old female had the history of chronic HCV infection for \>30 years and co-morbidity of depressive disorder and dementia under regular treatment with Quetiapine 50 mg/day. Due to fear of adverse events and underlying psychiatric disorder, she was ineligible to pegylated interferon/ribavirin, the current reimbursed regimen in Taiwan. The genotype and pretreatment viral loads was HCV-1b and 17,019 IU/mL (real-time HCV; Abbott Molecular, Des Plaines IL; detection limit: 12 IU/mL). The sonography revealed heterogeneous liver parenchyma without splenomegaly and visible collateral vessels. The result of the acoustic radiation force impulse (ARFI) was 1.3 m/s, which corresponded to fibrosis stage 2.^\[[@R2]\]^ Daily fixed-dose combination of paritaprevir/ritonavir/ombitasvir (150 mg/100 mg/25 mg) plus twice-daily dasabuvir (250 mg) was administered for the treatment of chronic HCV infection. Quetiapine was held transiently before antiviral therapy to avoid drug--drug interactions. The HCV ribonucleic acid (RNA) became rapidly undetectable on day 1, followed by day 7 and day 14 after dosing. Unfortunately, she was admitted due to fever, progressive thrombocytopenia, and elevated liver enzymes. Dengue fever infection with dengue virus genotype 2 (SYBR Green-based quantitative RT-PCR) infection was impressed on day 25 of treatment. She received supportive treatment with antipyretics (paracetamol 500 mg/time as needed) and intravenous fluids supply during hospitalization. PROD were terminated due to severe thrombocytopenia (7000/mm^3^). The patient discharged after 7 days supportive inpatient care for dengue fever. Dramatically, the serial testing of serum HCV RNA showed that the patient achieved SVR4, SVR8, and SVR12 (Table [1](#T1){ref-type="table"}). The patients provided written informed consent. The institutional review board in Kaohsiung Medical University Hospital approved the survey.
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Serial change of laboratory data and HCV RNA level of the patient.
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3. Discussion
=============

To our knowledge, this is the first report of DAA prescription that encountered dengue fever, and the patient benefited from HCV eradication only by 4 weeks of all oral DAA regimens. The current evidence support 12 to 24 weeks of interferon-free DAAs in treating CHC.^\[[@R1]\]^ An 8-week sofosbuvir/ledipasvir is recommended for naive, noncirrhotic HCV-1 patients with baseline viral loads \<8 million IU/mL.^\[[@R3]\]^ As observed in a phase 2b study that 8 weeks of PROD plus ribavirin had very high SVR rates for naive, noncirrhotic patients of HCV-1b (96%, 23/24) or with low viral loads (\<800,000 IU/mL, 100%, 9/9).^\[[@R4]\]^ The patient did not take any drug with potential drug--drug interaction with PROD. The achievement of SVR to only 25 days of PROD in this patient may attribute to HCV-1b with low baseline viral loads and extraordinarily rapid suppression of HCV after treatment Day 1. As with interferon-based therapy, the finding may shed light for possible response-guided-therapy for so-called ultra-super-responders in the DAA era.^\[[@R5]\]^ The strategy may be particular imperative in resource constrained countries. Notably, viral interference might exist in the same host. There are reciprocal suppressions between hepatitis B virus and HCV infections.^\[[@R6],[@R7]\]^ Whether the dengue virus, the Flaviviridae family as with HCV, enhances the HCV clearance remains unclear and needs further exploration.

Abbreviations: DAA = direct antiviral agents, HCV = hepatitis C virus, PROD = paritaprevir/ritonavir/ombitasvir/dasabuvir, SVR = sustained virological response.
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